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REVIEW OF THE DECISIONS OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES FOR CAPECITABINE FOR THE TREATMENT OF COLORECTAL CANCER
Saggia MG, Borges LG Roche Brazil, Sao Paulo, SP, Brazil OBJECTIVES: To conduct a review of the Health Technology Assessments (HTA) recommendations published on the International Network of HTA (INAHTA) website concerning the use of capecitabine to treat colorectal cancer in order to support the decision making in Brazil. METHODS: A search was conducted on INAHTA website (www.inahta.org), in English language, for the key word "capecitabine". Nineteen results were found, from which: 5 referred to other drugs; 6 to other capecitabine indication; 1 indicated an ongoing analysis, consequently, 7 results met our objective. RESULTS: The economic assessments found were conducted in Europe (6) and Argentina (1). All reports positively recommended the use of capecitabine. In the metastatic setting, the assessment made in 2003 by the NHS of Scotland and NICE (England) recommended capecitabine as an option for first line monotherapy; that of the NIHR Health Technology Assessment programme (England, 2003) showed that there are cost savings associated with the use of capecitabine and that of the IECS (Argentina, 2004) , concluded that capecitabine could be a therapeutic option with an easier administration and better safety profile. In the adjuvant setting, the NHSC (England, 2003) assessed that capecitabine may have a significant beneficial impact on patients, health services and staff. In 2006, NICE recommended capecitabine as monotherapy for patients with stage III (Dukes' C) colon cancer following surgery and the NIHR Health Technology Assessment programme showed that capecitabine is cost-effective in comparison with 5-FU/LV regimens. The authors also suggested that further research is necessary to compare effectiveness of capecitabine with other 5-FU/LV infusion regimens common used. CONCLUSIONS: According to this review, all published economic assessments up to the present date support the use of capecitabine for colorectal cancer (metastatic and adjuvant therapy).
PCN169 REVIEW OF THE DECISIONS OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES FOR CAPECITABINE FOR THE TREATMENT OF BREAST CANCER
Saggia MG, Borges LG Roche Brazil, Sao Paulo, SP, Brazil OBJECTIVES: To conduct a review of Health Technology Assessments (HTA) recommendations published on the International Network of HTA (INAHTA) website concerning use of capecitabine to treat breast cancer in order to support decision making in Brazil. METHODS: A search was conducted on INAHTA website (www. inahta.org), in English language, for the key word "capecitabine". Nineteen results were found, from which: 5 referred to other drugs; 10 to other capecitabine indications; consequently, 4 results met our objective. RESULTS: The economic assessments found were conducted in Europe (3) and Argentina (1). From these, 3 positively recommend the use of capecitabine for breast cancer and 1 did not state a clear recommendation, though considering that capecitabine seems to be a cost-effective therapy. The analysis conducted in 2003 by the NHS of Scotland for metastatic breast cancer, and that of the NICE (England) for locally advanced or metastatic breast cancer were replaced by NICE guidance CG81 (2009), which recommended capecitabine as monotherapy for second or third line in patients for whom anthracycline-containing regimens are unsuitable or have failed. In 2004, the IECS(Argentina), concluded that capecitabine can be a therapeutic option for locally advanced or metastatic breast cancer combined with docetaxel or as monotherapy. The assessment stated that capecitabine should be used when patients failed or are not eligible for anthracycline-containing regimens. The assessment by NIHR Health Technology Assessment programme (England, 2004) , indicated that capecitabine treatment as monotherapy or combined with docetaxel for locally advanced and/or metastatic breast cancer appears to be cost-effective. However, the authors stated that the evidence base for assessment was poor and further investigation is necessary. CONCLUSIONS: According to this review, the published economic assessments up to the present date suggest capecitabine as an option for the treatment of breast cancer (locally advanced or metastatic) for patients who failed or are not eligible for anthracyclinecontaining regimens. 3 The Christie NHS Foundation Trust, Manchester, UK OBJECTIVES: Due to wide variations in prescribing practice, a key methodological challenge for an economic analysis in oncology is describing current practice. Robust methods of eliciting the full range of expert opinion are necessary to ensure clinical relevance and validity of economic models. Insufficient information about variations in management can lead to model underestimation of uncertainty. This study aims to determine the appropriate model structure for an economic evaluation of a pharmacogenetic test to inform irinotecan prescribing, by identifying current practice. METHODS: Expert opinion was elicited to inform model structure. Through semistructured postal survey (May-August 2008) , clinical experts were asked to describe: the general management of advanced CRC patients on chemotherapy, place of irinotecan-based regimens within the clinical pathway and management of patients on these regimens. Since data on the frequency of key adverse events (neutropaenia and
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